Amgen posts higher revenue and net income on a profit-to-profit step-up, with an unresolved IRS transfer-pricing matter as the principal watch-item

Bottom line

For the three-month reporting period, Amgen Inc. reported a profit on both the bottom and operating lines, with revenue, operating income, net income and diluted earnings per share all higher than the prior-year comparative period. The authorized direction across each of these four metrics is an increase, and the authorized transition on the profit-side metrics is profit to profit. The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute this change to any single cause.

The reporting entity is Amgen Inc., trading under AMGN, filing on 10-Q for the fiscal period period-ended-2026-03-31. The filing carries accession 0000318154-26-000057 and is associated with CIK 0000318154. Both the three-month reporting period and its prior-year comparative are referenced through the period placeholders the three months ended March 31, 2026 and the three months ended March 31, 2025, respectively; the exact calendar dates are inserted by the machine after this section is published.

Revenue from Contract with Customer, Excluding Assessed Tax was $8,618,000,000 for the current reporting period and $8,149,000,000 for the prior-year comparative, both expressed in USD. Operating Income (Loss) was $2,666,000,000 for the current period and $1,178,000,000 for the prior year, both reported in USD, and each represents a profit. Net Income (Loss) Attributable to Parent was $1,819,000,000 for the current period and $1,730,000,000 for the prior year, both reported in USD, and each also represents a profit. Earnings Per Share, Diluted was $3.34 per diluted share USD/SHARES for the current period and $3.2 per diluted share USD/SHARES for the prior-year comparative.

The source scope for this section is the unaudited condensed consolidated financial information described in Item 1, which states that the interim figures have been prepared in accordance with GAAP, include only normal recurring adjustments, and should be read in conjunction with the most recent Annual Report on Form referenced in the same paragraph. Segment-level granularity for the dimensions cited above is not disclosed in the filing evidence at the level called for by this section. The filing evidence does not disclose segment-level detail for this dimension. Likewise, the filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. No causality statement is supported beyond the machine-owned line above.

A reader cross-checking the trend against a previously analysed life-sciences interim filing can compare the quarter-over-quarter pattern in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, noting that the second piece sits in a different issuer and form context but illustrates the same authorized direction of growth.

Financial performance

- For the three months ended March (omitted), Revenue from Contract with Customer, Excluding Assessed Tax was $8,618,000,000 USD, higher than the $8,149,000,000 USD reported for the prior-year comparative window. Operating Income (Loss) was $2,666,000,000 USD, higher than the $1,178,000,000 USD recorded a year earlier. Net Income (Loss) Attributable to Parent was $1,819,000,000 USD, higher than the $1,730,000,000 USD of the prior-year period. Earnings Per Share, Diluted was $3.34 per diluted share USD/SHARES, higher than the $3.2 per diluted share USD/SHARES reported in the comparative window. Each authorized year-over-year direction matched the prior period in character: revenue, operating income, net income and diluted EPS all moved from a profit base to a higher profit base across the two periods.

- Management offers no quantitative bridge explaining why revenue, operating income, net income, or diluted EPS shifted between windows. The condensed filing narrative notes that interim results are not necessarily indicative of full-year results and points readers to the prior Annual Report on Form (omitted) for additional context, but does not attribute the year-over-year movement to pricing, volume, mix, currency, or cost lines. The other segment items referenced in the cited segment note touch on litigation settlements and fair-value adjustments on equity securities (see Note 6), along with prior-period impairment charges on intangible assets (see Note 8), but the filing does not quantify their net effect on the current period or connect them to the headline income lines. The filing evidence does not attribute this change to any single cause.

- Accounting context is limited but worth flagging. Management confirms that certain prior-period amounts have been reclassified to conform with the current presentation, which means the prior-year comparatives shown above reflect any reclassifications rather than the originally reported figures. The Company reports in a single operating segment, human therapeutics, with the Chief Executive Officer acting as chief operating decision maker and net income serving as the segment measure of profit or loss (see Note 2). Two standards are in flight: a recently adopted derivatives and revenue standard that the Company states had no impact on the condensed statements, and a forthcoming expense-disaggregation standard under which management is still evaluating the disclosure effect.

- Comparison baselines are sparse. No peer or industry benchmark, no segment-level revenue or margin split, and no product-level revenue table are visible in the cited evidence. The narrative confirms one operating segment and consolidated review, leaving external comparators to the reader. The filing evidence contains no peer or industry comparison. Readers seeking a cross-company analog of an interim profit-to-profit step-up can compare the framing in Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows, which covers a similar year-over-year pattern though in a different industry.

- Guidance and expectations are absent from the visible filing excerpt: no forward-looking revenue, earnings, or margin statement, and no reaffirmed or withdrawn outlook language is quoted. Readers should treat the year-over-year results as historical and await a subsequent communication for any forward expectations.

Operating drivers and segments

- Operating Income (Loss) for the three months ended March 31, 2026 was $2,666,000,000 USD, compared with $1,178,000,000 USD for the three months ended March 31, 2025, an authorised increase with the current and prior periods both at a profit. - Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended March 31, 2026 was $8,618,000,000 USD, versus $8,149,000,000 USD for the three months ended March 31, 2025, an authorised increase with both periods positive. - The company operates as a single operating and reportable segment, human therapeutics, so segment performance is reported only on a consolidated basis and is not separately broken out beyond a small "other segment items" reconciliation.

- Management states, in the segment and other information note, that it operates in one operating segment, which also represents one reportable segment: human therapeutics. Results are therefore reported on a consolidated basis for segment reporting, consistent with internal management reporting. - The note explains that the human therapeutics segment is engaged in the discovery, development, manufacturing and delivery of innovative medicines, and that the determination of a single segment is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance and allocating resources, which is reviewed on a consolidated basis. - Management discloses that, because the CODM evaluates financial performance of the human therapeutics segment on a consolidated basis, the measure of segment performance is net income, as reflected in the Condensed Consolidated Statements of Income, and the measure of segment assets is total assets, as reflected in the Condensed Consolidated Balance Sheets. - For the three months ended March 31, 2025, the company states that other segment items included in Segment net income primarily consisted of (i) litigation settlements and (ii) fair value adjustments on equity securities (see Note 6). For the three months ended March 31, 2026, management states that other segment items included in Segment net income primarily consisted of fair value adjustments on equity securities (see Note 6) and impairment charges on intangible assets (see Note 8).

- The filing evidence does not separate revenue, cost of sales, R&D, SG&A, or operating-margin movements into a product-level or geographic breakdown, because the single-segment structure precludes that level of disclosure in this filing; readers evaluating period-over-period drivers therefore see only the consolidated top line, operating income and net income. Where the cause of a period-over-period movement is not addressed in the cited notes, The filing evidence does not attribute this change to any single cause..

- No peer or industry comparison is provided in the filing evidence, so any inference about the company's performance versus other human therapeutics issuers is unsupported here; The filing evidence contains no peer or industry comparison..

- Risk-factor, legal-proceedings and controls content referenced at Item 1A, Item 1, Item 2, Item 3, Item 4, Item 5 and Item 6 is not relied on for the operating-driver narrative in this section.

- Readers looking at another healthcare issuer's interim profit-to-profit pattern can cross-check the framing in Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows before drawing conclusions about this filing.

Cash flow and capital

- The three-month operating cash flow turned in a larger print than the prior-year comparative, with the reported figure for the three months ended March 31, 2026 rising relative to the three months ended March 31, 2025; both windows came in as positive cash generation. - Net Cash Provided by (Used in) Investing Activities stayed in negative territory in both periods, but the negative figure for the three months ended March 31, 2026 was a smaller outflow than the comparable figure for the three months ended March 31, 2025.

- Net Cash Provided by (Used in) Financing Activities swung from a negative reading in the three months ended March 31, 2025 to a positive reading in the three months ended March 31, 2026, marking a clear directional shift. - Payments to Acquire Property, Plant, and Equipment were higher in the three months ended March 31, 2026 than in the three months ended March 31, 2025, and Payments of Ordinary Dividends, Common Stock were also higher in the three months ended March 31, 2026 than in the three months ended March 31, 2025.

- On the balance sheet side, Cash and Cash Equivalents stood at $12,038,000,000 as of the balance sheet date of March 31, 2026, while Long-term Debt, Excluding Current Maturities was reported at $51,886,000,000 as of the same date. Accounts Payable, Current was carried at $2,935,000,000 as of the balance sheet date of March 31, 2026. - The combination of larger operating cash inflows, a smaller investing outflow, and a positive financing result is consistent with a quarter in which the company raised external financing while still ramping capital spending and continuing to return cash to shareholders.

The filing evidence does not attribute this change to any single cause. - The segment disclosure ties capital allocation back to the consolidated view: the CODM evaluates performance on a net income basis and manages assets on a consolidated basis, and the notes direct readers to Net cash used in investing activities in the Condensed Consolidated Statements of Cash Flows for further information regarding capital expenditures (see Note 6). The segment narrative is therefore consistent with the cash-flow picture — resources are allocated across functions, therapeutic areas, regions and R&D programs, with capital expenditures visible through the investing line.

- One external comparison worth flagging for context is the pattern seen in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which illustrates a similar year-over-year increase in cash returned to shareholders alongside rising operating cash flow. The filing evidence contains no peer or industry comparison. - Counter-evidence and gaps: the filing does not break out share repurchases from the financing line, does not disclose free cash flow as a defined subtotal, and does not quantify the split between maintenance and growth capital spending within Payments to Acquire Property, Plant, and Equipment.

The cash-flow statement itself also does not attribute the shift in financing cash flow to any single instrument or transaction. - Counter-evidence on leverage: Long-term Debt, Excluding Current Maturities as of the balance sheet date of March 31, 2026 sits alongside the cash balance disclosed on the same date, but the filing does not net the two or comment on net leverage, so any read on debt capacity versus liquidity remains qualitative rather than quantified here.

Peer and historical context

For AMGEN INC (AMGN), the comparison lens in this filing is strictly internal: a three-month read of the three months ended March 31, 2026 placed against the same three-month window a year earlier, the three months ended March 31, 2025. There is no peer-group evidence in this filing, so any cross-company read against large-cap biopharmaceutical names would be unsupported here.

On the internal historical axis, the top-line measure — Revenue from Contract with Customer, Excluding Assessed Tax — moved from $8,149,000,000 for the prior-year three-month window to $8,618,000,000 for the current three-month window. The filing presents this as a continuation of revenue growth rather than a recovery, given that product sales, hedging outcomes, and the segment construct discussed in the cited segment note (Note 2) were all consistent with a going-concern comparative rather than a step-change quarter. Below that line, Operating Income (Loss) climbed from $1,178,000,000 to $2,666,000,000, and Net Income (Loss) Attributable to Parent rose from $1,730,000,000 to $1,819,000,000, so profitability expanded in step with the top line rather than lagging behind it. The earnings-per-share section of the narrative ties diluted EPS to the same profit pool through the treasury-stock method, reinforcing that the year-over-year step is a same-store improvement rather than a share-count effect.

The cash side mirrors that pattern: Net Cash Provided by (Used in) Operating Activities went from $1,391,000,000 in the prior-year three-month period to $2,189,000,000 in the current three-month period, again higher, so the quarter was cash-generative in both windows. The MD&A text frames this through the effective tax-rate discussion, where the rate moved higher year over year, primarily reflecting the change in earnings mix, including lower amortization expense from acquisition-related assets, partially offset by the net unrealized losses on equity investments in the current-year period compared to net unrealized gains in the prior-year period, with the equity-investment context cross-referenced in Note 6. That mix shift is described as a passive result of the underlying earnings composition rather than a deliberate tax-rate reset.

There are no numbers for cost of sales, R&D, SG&A, segment revenue splits, or individual product performance in this section's catalog, so a margin-walk versus a year ago cannot be reconstructed from the evidence supplied. Segment-level breakdown beyond the high-level reference in Note 2 is also not available in the text.

The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

Scenario analysis

- Reported facts: For the three-month period covered by this 10-Q filing for AMGEN INC (CIK 0000318154, accession 0000318154-26-000057, fiscal period period-ended-2026-03-31, ticker AMGN), revenue is reported at $8,618,000,000 USD versus $8,149,000,000 USD, with the authorized direction increase from the prior-year three-month window the three months ended March 31, 2025 to the current three-month window the three months ended March 31, 2026. Net Income (Loss) Attributable to Parent sits at $1,819,000,000 USD versus $1,730,000,000 USD, again authorized direction increase, with the authorized transition profit to profit on both sides.

- Management explanations: The filing's segment and tax commentary (per the cited segment note and the income-tax discussion that references UTB balances and IRS disputes around intercompany profit allocation) is the qualitative backdrop management puts around those numbers, but management does not commit to a single narrative driver that ties the quarter's top-line and bottom-line step-up to one specific product, geography, or pricing lever. - Analyst inference: Because revenue and net income are both positive in the comparison and both move in the same authorized direction, a steady-state continuation in which the prior-year run rate extends forward with similar product economics is consistent with the disclosed data, and the segment note referenced as Note 2 points to a single operating segment framework which limits the ability to decompose the move by business unit.

S. " That unresolved exposure is the clearest counterweight to the quarter's reported profitability and is the kind of tail item the segment note Note 8 and goodwill/intangible disclosures do not absorb. - Unknowns: The filing does not break out pricing, volume, or currency effects that would let an analyst decompose the revenue step-up; The filing evidence does not disclose segment-level detail for this dimension..

It also does not disclose a peer or industry benchmark against the quarter's results; The filing evidence contains no peer or industry comparison.. The change in UTBs during the quarter is described directionally but no quantified reconciliation is given, and management does not attribute the period's earnings move to any one cause; The filing evidence does not attribute this change to any single cause.. - Base case anchors on the reported profit-to-profit progression: revenue at $8,618,000,000 USD and net income at $1,819,000,000 USD, with the same authorized direction increase on both lines, treated as the central tendency for the period.

- Upside case layers on a continuation of the authorized direction increase on revenue and net income into the next reporting window, assuming the IRS matters described in the cited income-tax discussion are resolved without a material cash impact and pricing on the existing product mix holds, while acknowledging that the same authorized direction increase already in this period limits how much incremental upside can be claimed from disclosed data alone. - Downside case centers on the unresolved tax exposure: if the draft NOPA referenced in the filing is sustained in part, the period's reported profitability could be eroded by a material non-cash accrual movement, even though the authorized direction increase on net income would still describe the as-reported number for this quarter.

Risks and what to watch

The principal forward-looking risk disclosed in the filing sits in 10-Q period-ended-2026-03-31 under accession 0000318154-26-000057 for AMGEN INC (ticker AMGN, CIK 0000318154) and concerns an ongoing IRS examination that could materially affect the tax position. The company received a draft notice of proposed adjustment covering earlier years that principally relates to the allocation of profits between United States entities and foreign jurisdictions. Management has formally disagreed with the methodology and is contesting it, but the company itself flags that, if sustained in full, the adjustments "could have a material impact on our financial statements." A separate audit cycle is expected to begin in the first half of the next year and may revisit the same transfer-pricing theme, while final resolution of the existing matters is not anticipated within the next twelve months. The UTB rollforward disclosed in the cited note also shows that gross unrecognized tax benefits grew during the three months, indicating that the exposure is not static.

Reported facts - Revenue from Contract with Customer, Excluding Assessed Tax was $8,618,000,000 USD for the three months ended March 31, 2026, and $8,149,000,000 USD for the three months ended March 31, 2025; the authorized year-over-year direction is increase. - Net Income (Loss) Attributable to Parent was $1,819,000,000 USD for the three months ended March 31, 2026, and $1,730,000,000 USD for the three months ended March 31, 2025; the authorized year-over-year direction is increase, with a profit-to-profit transition.

Management explanations The IRS draft NOPA and the anticipated continuation of similar audit themes for later years are presented as the dominant tax risk. Management believes its income tax accrual is appropriate based on past experience, interpretations of tax law, and judgments about tax-authority positions, but acknowledges that the ultimate outcome "may result in payments substantially greater than amounts accrued" and "could have a material adverse impact on our condensed consolidated financial statements."

Analyst inference The tax exposure is a single-issue concentration rather than a broad operational risk, and the contingency language is conditional on the IRS prevailing on methodology. Because the company is actively disputing and has identified favorable Tax Court precedent, the disclosed exposure reflects a worst-case scenario rather than a probable outcome.

Counter-evidence The same filing shows revenue and net income both moving higher year over year, which cuts against the narrative of an underlying earnings deterioration. Investment policy language in the cited note emphasizes safety of principal, prudent liquidity, investment-grade issuer limits, and restrictions on maturities and concentration, which tempers concerns about portfolio credit risk on interest-bearing securities.

Unknowns The specific dollar magnitude of the draft NOPA adjustment is not disclosed in the quoted evidence, the UTB addition is shown only as a gross movement with the precise figure redacted, and the timing of any settlement beyond the next twelve months is open. The filing evidence does not attribute this change to any single cause. Segment-level breakdowns for revenue and net income are not provided in the quoted text.

Metrics to watch next period - Movement in the gross UTB balance and any cash settlement with the IRS, including the start of the next audit cycle for later years. - Year-over-year trajectory of Revenue from Contract with Customer, Excluding Assessed Tax against the prior-year base, and whether the prior-period increase is sustained. - Year-over-year trajectory of Net Income (Loss) Attributable to Parent, and whether the prior-period profit-to-profit transition is preserved. - Realized gains and losses on interest-bearing securities, given the investment policy emphasis on safety and liquidity.